Sharsheret to Present Part Two of Clinical Trials Webinar Series
Contact: Elana Silber, Director of Operations
Telephone: 866.474.2774
Email: [email protected]
Teaneck, New Jersey (February 2, 2015) – Sharsheret, a national not-for-profit organization supporting young women and their families, of all Jewish backgrounds, facing breast cancer will present Part Two of “Clinical Trials in a New Age,” a free, national webinar series. “How You Can Connect,” will take place on Wednesday, February 25, 2015, 8:00 p.m. (EST). An audio recording and written transcript of “Part One: What You Need to Know” is now available online at www.sharsheret.org.
The series features presentations about clinical trials in the BRCA and hereditary cancer community. “Part Two: How You Can Connect,” will feature a presentation from Susan Domcheck, MD, Executive Director, Basser Research Center, on accessing, researching, and participating in clinical trials. Additionally, Shera Dubitsky, MEd, MA, Director of Navigation and Support Services, Sharsheret, will highlight the unique concerns of Jewish women and families participating in clinical trials, and a Sharsheret volunteer will share her personal story. A live question and answer session will follow the presentations.
“Women, particularly those in the BRCA community, reach out to Sharsheret with pressing questions about clinical trials at all stages of their cancer journeys,” said Director of Support Programs Adina Fleischmann. “The upcoming webinar will empower women who are BRCA positive, high risk, or living with breast cancer or ovarian cancer in our community with critical information and tools about researching, accessing, and participating in clinical trials.”
To register for the upcoming webinar and for log-in instructions, visit www.sharsheret.org or call toll-free 866.474.2774. This series is made possible with generous support from AstraZeneca and Provectus Biopharmaceuticals, Inc.
About Sharsheret
Sharsheret, Hebrew for “chain”, is a national not-for-profit organization supporting young women and their families, of all Jewish backgrounds, facing breast cancer. Our mission is to offer a community of support to women diagnosed with breast cancer or at increased genetic risk, by fostering culturally-relevant individualized connections with networks of peers, health professionals, and related resources.
Since Sharsheret’s founding in 2001, we have responded to more than 45,000 breast cancer inquiries, involved more than 4,000 peer supporters, and presented over 250 educational programs nationwide. Sharsheret supports young Jewish women and families facing breast cancer at every stage – before, during, and after diagnosis. We help women and families connect to our community in the way that feels most comfortable, taking into consideration their stage of life, diagnosis, or treatment, as well as their connection to Judaism. We also provide educational resources, offer specialized support to those facing ovarian cancer or at high risk of developing cancer, and create programs for women and families to improve their quality of life. All Sharsheret programs are open to all women and men.
Sharsheret offers the following national programs:
The Link Program
• Peer Support Network, connecting women newly diagnosed or at high risk of developing breast cancer one-on-one with others who share similar diagnoses and experiences
• EmbraceTM, supporting women living with advanced breast cancer
• Genetics for Life®, addressing hereditary breast and ovarian cancer
• Thriving Again®, providing individualized support, education, and survivorship plans for young breast cancer survivors
• Busy Box®, for young parents facing breast cancer
• Best Face Forward®, addressing the cosmetic side effects of treatment
• Family Focus®, providing resources and support for caregivers and family members
• Ovarian Cancer Program, tailored resources and support for young Jewish women and families facing ovarian cancer
• Sharsheret SupportsTM, developing local support groups and programs
Education and Outreach Programs
• Health Care Symposia, on issues unique to younger women facing breast cancer
• Sharsheret on Campus, outreach and education to students on campus
• Sharsheret Educational Resource Booklet Series, culturally-relevant publications for Jewish women and their families and healthcare professionals
About AstraZeneca
For more information about AstraZeneca, please visit www.astrazeneca.com.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, SVP – Investor Relations
Phone: 212-564-4700
Bill Gordon – Media Relations
Phone: 212-724-6312